vastatin Survival Study (4S).
Lancet 1994;344:1383-9.
69. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic
Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
70. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD,
Cole TG, et al. The effect of pravastatin on coronary events after
myocardial infarction in patients with average cholesterol levels.
Cholesterol and Recurrent Events Trial investigators. N Engl J Med
1996;335:1001-9.
71. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT,
Hunninghake DB, et al. Implications of recent clinical trials for the
National Cholesterol Education Program Adult Treatment Panel III
guidelines. Circulation 2004;110:227-39.
72. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with
atorvastatin improves walking distance in patients with peripheral
arterial disease. Circulation 2003;108:1481-6.
73. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T,
Agricola E, et al. Effects of simvastatin on walking performance
and symptoms of intermittent claudication in hypercholesterolemic
patients with peripheral vascular disease. Am J Med 2003;114:
359-64.
74. Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DJ,
Reynolds MR, et al. Supervised exercise versus primary stenting for
claudication resulting from aortoiliac peripheral artery disease: sixmonth outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation 2012;125:
130-